Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trialStephen A. Boorjian, Colin P. Dinney, Neal D. Shore et al.|The Lancet Oncology|2020Cited by 459
Intravesical rAd–IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin–Refractory or Relapsed Non–Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D. Shore, Colin P. Dinney, Stephen A. Boorjian et al.|Journal of Clinical Oncology|2017Cited by 175
Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter StudySiamak Daneshmand, Sanjay Patel, Yair Lotan et al.|The Journal of Urology|2017Cited by 109
Emerging Impact of Malnutrition on Surgical Patients: Literature Review and Potential Implications for Cystectomy in Bladder CancerConrad M. Tobert, Kenneth G. Nepple, Jill Hamilton‐Reeves et al.|The Journal of Urology|2017Cited by 90
Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018Yair Lotan, Siamak Daneshmand, Trinity J. Bivalacqua et al.|Nature Reviews Urology|2019Cited by 84